Nano Dimension defends Infinite Epigenetics deal amid shareholder pushback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination
June 16, 2026 7:43 PM EDTWALTHAM, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (Nano Dimension, Nano, or the Company) and Infinite Epigenetics (Infinite Epigenetics, Infinite) today issued the following shareholder update to provide additional detail on the proposed business combination announced on June 15, 2026. The Company has carefully reviewed Murchinsons recent letter regarding the proposed transaction with Infinite. While we welcome shareholder engagement... More
